Literature DB >> 8706038

Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue.

I Preuss1, S Haas, U Eichhorn, I Eberhagen, M Kaufmann, T Beck, R H Eibl, P Dall, T Bauknecht, J Hengstler, B M Wittig, W Dippold, B Kaina.   

Abstract

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is a main determinant of resistance of cells towards the cytostatic effect of N-nitrosoureas. Here we report the activity of MGMT in different types of human tumors. Colorectal tumors showed the highest mean of MGMT activity (481 +/- 258 fmol/mg protein) followed by ovarian tumors (437 +/- 291 fmol/mg), breast (306 +/- 204 fmol/mg), testicular (299 +/- 179 fmol/mg), and brain tumors (55 +/- 44 fmol/mg). Only in breast and brain tumors were MGMT-deficient samples found, with a frequency of 3 and 5%, respectively. No significant difference in mean MGMT activity was observed between breast tumors of grading I, II, and III. For brain tumors there was a tendency of MGMT to decline with increasing grading. Breast and colorectal carcinomas were compared with the corresponding normal tissue obtained from the same patient. The data showed for 11 out of 12 pairs of breast tissue and for 13 out of 15 pairs of colorectal tissue that MGMT activity in the tumor was equal to or, more frequently, higher than the activity found in the corresponding normal tissue. Thus, it appears that in these groups of tumors, increase of MGMT activity during tumor formation and progression is the rule rather than the exception.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706038

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  8 in total

1.  Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.

Authors:  Prabal Deb; N S Mani; S M Sudumbrekar; Nitin Taneja; Seema Patrikar
Journal:  Med J Armed Forces India       Date:  2012-12-01

2.  BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.

Authors:  Jie Ding; Shaofang Wu; Chen Zhang; Arnav Garyali; Emmanuel Martinez-Ledesma; Feng Gao; Adarsha Pokkulandra; Xiaolong Li; Christopher Bristow; Alessandro Carugo; Dimpy Koul; Wk Alfred Yung
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

3.  Polymorphisms of the DNA repair gene MGMT and risk and progression of head and neck cancer.

Authors:  Zhengdong Zhang; Luo Wang; Sheng Wei; Zhensheng Liu; Li-E Wang; Erich M Sturgis; Qingyi Wei
Journal:  DNA Repair (Amst)       Date:  2010-03-04

4.  MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Authors:  George C Bobustuc; Joshua S Smith; Sreeram Maddipatla; Sheila Jeudy; Arati Limaye; Beth Isley; Maria-Lourdes M Caparas; Susan M Constantino; Nikita Shah; Cheryl H Baker; Kalkunte S Srivenugopal; Said Baidas; Santhi D Konduri
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

Review 5.  Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Authors:  Bernd Kaina; Geoffrey P Margison; Markus Christmann
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

6.  Immunohistochemical Assessment of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and Its Relationship with p53 Expression in Endometrial Cancers.

Authors:  Kyung Eun Lee
Journal:  J Cancer Prev       Date:  2013-12

7.  MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.

Authors:  Olivier J Switzeny; Markus Christmann; Mirjam Renovanz; Alf Giese; Clemens Sommer; Bernd Kaina
Journal:  Clin Epigenetics       Date:  2016-05-05       Impact factor: 6.551

8.  O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma.

Authors:  Shang-Hung Chen; Wen-Tsung Huang; Wan-Chen Kao; Sheng-Yen Hsiao; Hsin-Yi Pan; Chin-Wen Fang; Yow-Ling Shiue; Chia-Lin Chou; Chien-Feng Li
Journal:  J Biomed Sci       Date:  2021-01-04       Impact factor: 8.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.